Dosimetric Analysis and Clinical Outcome of Cobalt-60 Based HDR Brachytherapy in Carcinoma Cervix: A Prospective Study
International Journal of Current Pharmaceutical Review and Research · 30.07.2026 · 18 (07)
DOI: 10.25258/ijcpr.18.7.34 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Current Pharmaceutical Review and Research, online erschienen am 30.07.2026. Verfasst von Ashar Iqbal Lodi und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
Carcinoma cervix is a major health concern in developing countries. High dose rate (HDR) intracavitary brachytherapy (ICBT) following external beam radiotherapy (EBRT) is a crucial part of definitive treatment. The introduction of CT-based image-guided brachytherapy (IGBT) enables improved target coverage and sparing of organs at risk (OARs).
Aim
To evaluate dosimetric parameters, acute toxicities and early clinical response in patients undergoing CTbased HDR brachytherapy using a cobalt-60 (Co-60) source. Materials and Methods: This prospective observational study included 20 patients with histologically confirmed carcinoma cervix (FIGO 2018 stages IIA–IIIB). All patients received EBRT (50 Gy in 25 fractions) with concurrent weekly cisplatin (40 mg/m²), followed by HDR brachytherapy (7 Gy × 3 weekly fractions). CTbased planning was performed according to American Brachytherapy Society guidelines. Dosimetric parameters including HR-CTV D90 and OAR D2cc doses were converted to EQD2. Acute toxicities were graded using CTCAE v5.0 and response was assessed clinically.
Results
The mean HR-CTV D90 EQD2 was 84.82 Gy. Mean D2cc doses to bladder, rectum, and sigmoid were 72.93 Gy, 65.62 Gy and 62.06 Gy, respectively, all within recommended tolerance limits. Acute toxicities were predominantly Grade 1–2, with no Grade ≥3 events observed. Complete response was achieved in 90% of patients.
Conclusion
CT-guided HDR brachytherapy using Cobalt-60 is an effective and practical treatment approach for carcinoma cervix. It provides promising results with adequate target coverage with acceptable OAR sparing and minimal acute toxicity.
Zitieren
APA
Lodi, A. I., Karnawat, S., Bhandari, V., & Kaushik, S. (2026). Dosimetric Analysis and Clinical Outcome of Cobalt-60 Based HDR Brachytherapy in Carcinoma Cervix: A Prospective Study. International Journal of Current Pharmaceutical Review and Research, 18(07). https://doi.org/10.25258/ijcpr.18.7.34
Vancouver
Lodi AI, Karnawat S, Bhandari V, Kaushik S. Dosimetric Analysis and Clinical Outcome of Cobalt-60 Based HDR Brachytherapy in Carcinoma Cervix: A Prospective Study. International Journal of Current Pharmaceutical Review and Research. 2026;18(07). doi:10.25258/ijcpr.18.7.34
BibTeX
@article{Lodi2026,
author = {Lodi, Ashar Iqbal and Karnawat, Saurabh and Bhandari, Virendra and Kaushik, Shweta},
title = {Dosimetric Analysis and Clinical Outcome of Cobalt-60 Based HDR Brachytherapy in Carcinoma Cervix: A Prospective Study},
journal = {International Journal of Current Pharmaceutical Review and Research},
year = {2026},
volume = {18},
number = {07},
doi = {10.25258/ijcpr.18.7.34}
}
EUVIMED